Clinical Observation of FMD Regimen:Fludarabine,Mitoxantrone,Dexamethasone,in Treatment of Non-Hodgkin's Lymphoma  

作　　者：Shuqing Lu Jianmin Wang Xianmin Song Li Chen Weiping Zhang Jun Hou Xiaoqian Xu Chongmei Huang Jianmin Yang 

机构地区：[1]Department of Hematology, Changhai Hospital, Second Military Medical University,Shanghai 200433, China

出　　处：《Chinese Journal of Clinical Oncology》2008年第6期433-436,共4页中国肿瘤临床（英文版）

摘　　要：OBJECTIVE To evaluate the clinical effectivity and toxicity of the regimen FMD （fludarabine, mitoxantrone, dexamethasone） in patients with non-Hodgkin＇s lymphoma. METHODS Thirty-two patients, twenty-four of whom had indolent B-cell lymphoma, 6 peripheral T-cell lymphoma, two diffuse large B-cell lymphoma, received FMD. Treatment comprised： fludarabine 25-30 mg/m^2 days 1-3, mitoxantrone 8-10 mg/m^2 day 1, and dexamethasone 20-30 mg/m^2 days 1-5. At the same time, patients received prophylaxis against conditional infection with trimethoprim-sulfamethoxazole, fluconazole, acyclovir and immunoglobulin. RESULTS Of the thirty-two patients treated, the complete response （CR） rate, partial response （PR） rate and overall response （OR） rate were 56.3%, 21.9% and 78.2% respectively. The CR and OR rate of 24 patients with indolent B-cell lymphoma were 66.7% and 88.3% respectively. Two of six patients with peripheral T-cell lymphoma were of complete response type and one was of partial response type. One of two patients with diffuse large B-cell lymphoma was partial response. The dominating toxicity was myelotoxicity and immunotoxicity. There was no treatment associated death in all patients treated with FMD. Grade 3-4 neutropenia occurred in 43.8% patients, 12.5% patients had infections and 9.3% developed grade 3-4 thrombocytopenia. At a median follow-up of 24 （5-54） months, the 2-year overall-survival rate and progression-free survival rate were （87.5 ± 1.4）% and （83.3 ± 1.6）% respectively. The 2-year OS and PFS rates of the indolent group were （93.75 ± 6.25）% and （87.5 ± 8.54）%. CONCLUSION FMD regimen was highly effective with low toxicity in the treatment of non-Hodgkin＇s lymphoma, especially in indolent B-cell lymphoma. It also helps to improve the prognosis even in some aggressive lymphoma, such as peripheral T cell lymphoma.OBJECTIVE To evaluate the clinical effectivity and toxicity ofthe regimen FMD (fludarabine,mitoxantrone,dexamethasone) inpatients with non-Hodgkin's lymphoma.METHODS Thirty-two patients,twenty-four of whom hadindolent B-cell lymphoma,6 peripheral T-cell lymphoma,two diffuse large B-cell Iymphoma,received FMD.Treatmentcomprised:fludarabine 25～30 mg/m^2 days 1～3,mitoxantrone8～10 mg/m^2 day 1,and dexamethasone 20～30 mg/m2 days 1～5.Atthe same time,patients received prophylaxis against conditionalinfection with trimethoprim-sulfamethoxazole,fluconazole,acyclovir and immunoglobulin.RESULTS Of the thirty-two patients treated,the completeresponse (CR) rate,partial response (PR) rate and overall response(OR) rate were 56.3%,21.9% and 78.2% respectively.The CRand OR rate of 24 patients with indolent B-cell lymphoma were66.7% and 88.3% respectively.Two of six patients with peripheralT-cell lymphoma were of complete response type and one wasof partial response type.One of two patients with diffuse largeB-cell lymphoma was partial response.The dominating toxicitywas myelotoxicity and immunotoxicity.There was no treatmentassociated death in all patients treated with FMD.Grade 3～4neutropenia occurred in 43.8% patients,12.5% patients hadinfections and 9.3% developed grade 3～4 thrombocytopenia.At amedian follow-up of 24 (5～54) months,the 2-year overall-survivalrate and progression-free survival rate were (87.5±1.4)% and (83.3±1.6)% respectively.The 2-year OS and PFS rates of the indolentgroup were (93.75±6.25)% and (87.5±8.54)%.CONCLUSION FMD regimen was highly effective with lowtoxicity in the treatment of non-Hodgkin's lymphoma,especiallyin indolent B-cell lymphoma.It also helps to improve theprognosis even in some aggressive lymphoma,such as peripheralT cell lymphoma.

关 键 词：FLUDARABINE MITOXANTRONE DEXAMETHASONE lymphoma non-Hodgkin＇s. 

分 类 号：R733[医药卫生—肿瘤]